ReviewTherapeutics and clinical risk management2016
A critical appraisal of atomoxetine in the management of ADHD.
Review in Therapeutics and clinical risk management, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 62 citations in OpenAlex.
- A phase II study repurposing atomoxetine for neuroprotection in mild cognitive impairment.Brain : a journal of neurology · 2022Trial
- Response inhibition and emotional cognition improved by atomoxetine in children and adolescents with ADHD: The ACTION randomized controlled trial.Journal of psychiatric research · 2018Trial
- Pharmacokinetics at Different Application Sites and Dermal Safety Analysis of Dextroamphetamine Transdermal System (d-ATS) in Healthy Adults and Patients with ADHD.Advances in therapy · 2026Article
- Revisiting the Role of Serotonin in Attention-Deficit Hyperactivity Disorder: New Insights from Preclinical and Clinical Studies.Clinical drug investigation · 2025Review
- Attention-deficit hyperactivity disorder medication shortage in the United States: a qualitative assessment of Reddit posts.Frontiers in pharmacology · 2025Article
- Extended-Release Viloxazine Compared with Atomoxetine for Attention Deficit Hyperactivity Disorder.CNS drugs · 2023Article
- The Impact of Acupuncture on Self-Perceived Stress and ADHD Core Symptomatology in an Adult, Atomoxetine-taking ADHD Participant. Insights from an In-depth Single Case Study.Integrative medicine (Encinitas, Calif.) · 2023Review
- Cognitive Test Solution in Mice with Different Brain Weights after Atomoxetine.Neurology international · 2023Article
- Personalizing atomoxetine dosing in children with ADHD: what can we learn from current supporting evidence.European journal of clinical pharmacology · 2023Review
- DRAGON-Data: a platform and protocol for integrating genomic and phenotypic data across large psychiatric cohorts.BJPsych open · 2023Article
- An overview on neurobiology and therapeutics of attention-deficit/hyperactivity disorder.Discover mental health · 2023Review
- Review
- Pharmacological interventions for Problematic Usage of the Internet (PUI): A narrative review of current progress and future directions.Current opinion in behavioral sciences · 2022Article
- "Jing-Ning Granules" Can Alleviate Attention Deficit Hyperactivity Disorder in Rats by Modulating Dopaminergic D2/D1-Like Receptor-Mediated Signaling Pathways.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- ADHD: Reviewing the Causes and Evaluating Solutions.Journal of personalized medicine · 2021Review
- The Mechanism, Clinical Efficacy, Safety, and Dosage Regimen of Atomoxetine for ADHD Therapy in Children: A Narrative Review.Frontiers in psychiatry · 2021Review
- Metabolic profiling of norepinephrine reuptake inhibitor atomoxetine.European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences · 2020Article
- Treatment of adult ADHD: a clinical perspective.Therapeutic advances in psychopharmacology · 2018Review
- Identification of biotypes in Attention-Deficit/Hyperactivity Disorder, a report from a randomized, controlled trial.Personalized medicine in psychiatry · 2017Article
- The Effect of Myricetin on Pharmacokinetics of Atomoxetine and its Metabolite 4-Hydroxyatomoxetine In Vivo and In Vitro.European journal of drug metabolism and pharmacokinetics · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Attention-deficit/hyperactivity disorder (ADHD) is a common neurobehavioral disorder beginning in childhood and often continuing into adulthood. A wealth of data shows that ADHD symptoms respond well to pharmacological treatment. Stimulant medications, including amphetamine and methylphenidate, are most commonly used to treat ADHD. However, with the approval of atomoxetine (Strattera(®), [ATX]) by the US Food and Drug Administration in late 2002, an effective non-stimulant option became available. The US Food and Drug Administration approved ATX for the treatment of ADHD in children, adolescents, and adults. Although the effect size of ATX is generally lower than that of stimulants, the American Academy of Child and Adolescent Psychiatry Practice Parameter for the treatment of ADHD lists ATX as a first-line treatment option. ATX is widely prescribed and accounted for 6% of the prescriptions of ADHD visits in the US in 2010. Numerous trials have found that ATX improves quality of life and emotional lability in addition to core ADHD symptoms. Although some improvement may be seen in a patient as early as one week after the initiation of treatment, ATX generally takes longer to have a full effect. The median time to response using 25% improvement in ADHD symptoms in pooled trials was 3.7 weeks. Data from these trials indicate that the probability of symptom improvement may continue to increase up to 52 weeks after treatment is initiated. ATX has been shown to be safe and effective in combination with stimulants. It has also been studied systematically in subjects with ADHD and comorbid oppositional defiant disorder, anxiety, depression, and substance use disorders. The mechanism of action of ATX, its efficacy, and adverse events reported in trials is reviewed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.